Showing results (371-380 of 488) with videos related to

Sort By:
Pageof 49
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 7, 2023
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled TrialJustin Stebbing, Yauheni Baranau, Valery Baryash, et al.
Oncogene|March 16, 2018
LMTK3 confers chemo-resistance in breast cancerJustin Stebbing, Kalpit Shah, Lei Cheng Lit, et al.
Science Signaling|June 19, 2014
The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁Yichen Xu, Hua Zhang, Lei C Lit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2016
Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell CountsJacqueline A Shaw, David S Guttery, Allison Hills, et al.
Cancer Research|November 11, 2020
SCIRT lncRNA Restrains Tumorigenesis by Opposing Transcriptional Programs of Tumor-Initiating CellsSladjana Zagorac, Alex de Giorgio, Aleksandra Dabrowska, et al.
Endocrine-Related Cancer|June 30, 2016
MicroRNAs associated with small bowel neuroendocrine tumours and their metastasesHelen C Miller, Adam E Frampton, Anna Malczewska, et al.
Breast (Edinburgh, Scotland)|April 10, 2016
The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane ProjectAnthony J Maxwell, Karen Clements, David J Dodwell, et al.
Breast Cancer Research : BCR|November 20, 2012
ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFRChristoforos Thomas, Gayani Rajapaksa, Fotis Nikolos, et al.
BMJ Open|March 14, 2019
The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)E Shelley Hwang, Terry Hyslop, Thomas Lynch, et al.
Breast Cancer Research and Treatment|April 6, 2012
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept studyMarta Pestrin, Silvia Bessi, Fabio Puglisi, et al.
Pageof 49